CLDN6 and cancer: For example, CLDN4 overexpression, an indicator of poor clinical outcome in patients with ovarian cancer, is an indicator of resistance to cisplatin in this cancer type [18,19], and a similar role for CLDN6 is seen in cervical adenocarcinoma [20].